ライフサイエンスコーパス: DTPA

1 (DTPA)(n)-trastuzumab-(IRDye800)(m) showed significantly

2 DTPA-conjugation and (111)In-labeling did not change tel

3 DTPA-extractable soil Fe and grain Fe concentration were

4 DTPA-extractable soil Zn concentration was more than two

5 DTPA-extractable Zn in soils grown with IR69428 was posi

6 ow was determined by pretreatment indium-111-DTPA studies.

7 hyldiethylenetriamine pentaacetic acid (1B4M-DTPA), bearing either an isothiocyanate or a succinimidy

8 paration of a novel maleimide analog of 1B4M-DTPA from a key synthetic intermediate aniline derivativ

9 other hand, we found that the agent bis-5HT-DTPA-Gd utilizes both mechanisms when activated.

10 extremes in either oligomerization (mono-5HT-DTPA-Gd) or protein-binding in their activation mechanis

11 IDDS system of the drug, radiotracer (99mTc-DTPA) solution was injected into the pump reservoir.

12 removed from EP-2104R by a challenge with a DTPA based ligand, while the commercial contrast agents

13 Panitumumab was conjugated to CHX-A''-DTPA and radiolabeled with (86)Y.

14 adiolabeled with (177)Lu through the CHX-A''-DTPA chelator.

15 gated to a 100-nm diameter liposomal-CHX-A''-DTPA construct, upon which the rat HER2/neu reactive ant

16 iethylene-triamine-pentaacetic acid (CHX-A''-DTPA)/linker construct to the EGFR-directed antibody cet

17 (a) 19.2 MBq (520 muCi) of liposome-CHX-A''-DTPA-(213)Bi, (b) 19.2 MBq of liposome-CHX-A''-DTPA-(213

18 PA-(213)Bi, (b) 19.2 MBq of liposome-CHX-A''-DTPA-(213)Bi-7.16.4, (c) 4.44 MBq (120 muCi) of (213)Bi-

19 d (d) cold (nonradioactive) liposome-CHX-A''-DTPA-7.16.4 as control.

20 (90)Y-Y-CHX-A''-DTPA-cetuximab affected cell survival through the induct

21 Exposure to (90)Y-Y-CHX-A''-DTPA-cetuximab also resulted in efficient cell killing,

22 ted radioimmunotherapy using (90)Y-Y-CHX-A''-DTPA-cetuximab appears to be a powerful tool that can be

23 antibody cetuximab to yield (90)Y-Y-CHX-A''-DTPA-cetuximab with a specific activity of approximately

24 When cells were exposed to (90)Y-Y-CHX-A''-DTPA-cetuximab, the number of induced DSBs increased lin

25 demonstrates the potential of (86)Y-CHX-A''-DTPA-panitumumab for quantitative noninvasive PET of HER

26 (86)Y-CHX-A''-DTPA-panitumumab was routinely prepared with a specific

27 0.005 M diethylenetriaminepentaacetic acid (DTPA) (pH 7.6) extraction fluid at selected times over 3

28 dolinium-diethylenetriaminepentaacetic acid (DTPA) as a contrast agent for MR imaging and (18)F-FDG,

29 A x anti-diethylenetriaminepentaacetic acid (DTPA) bispecific antibody (hMN-14 x m734) (40 mg/m(2)),

30 such as diethylenetriaminepentaacetic acid (DTPA) derivatives, dissociation-enhanced lanthanide fluo

31 CHX-A''-diethylenetriaminepentaacetic acid (DTPA) or benzyl-DTPA conjugated to a recombinant immunog

32 ition of diethylenetriaminepentaacetic acid (DTPA) to allow (111)In labeling or the fluorophore Cy3.

33 (99m)Tc-diethylenetriaminepentaacetic acid (DTPA) was also estimated as a reference.

34 (111)In-diethylenetriaminepentaacetic acid (DTPA) with the standardized (99m)Tc-labeled solid meal.

35 d (NTA), diethylenetriaminepentaacetic acid (DTPA), and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra

36 dolinium-diethylenetriaminepentaacetic acid (DTPA), bolus injection of (18)F-FDG, bolus injection of

37 -(111)In-diethylenetriaminepentaacetic acid (DTPA)-anti-PD-L1-to identify PD-L1-positive tumors in vi

38 ium (Gd)-diethylenetriaminepentaacetic acid (DTPA)-bis(stearylamide) and DiI dye were used to label m

39 (111)In-diethylenetriaminepentaacetic acid (DTPA)-labetuzumab-IRDye800CW can detect pulmonary microm

40 (111)In-diethylenetriaminepentaacetic acid (DTPA)-MN-14-IRDye 800CW and performed 4 studies on mice

41 (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implem

42 (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the nuclear m

43 -CHX-A''-diethylenetriaminepentaacetic acid (DTPA)-panitumumab for quantitative PET of HER1-expressin

44 (111)In-diethylenetriaminepentaacetic acid (DTPA)-Tyr3-octreotate.

45 213)Bi-diethylene triamine pentaacetic acid (DTPA) in mouse models was performed.

46 agent diethylene triamine pentaacetic acid (DTPA) significantly reduced H2O2 generation.

47 TA) and diethylenetriamine pentaacetic acid (DTPA) were found to increase Cu translocation to shoot t

48 111)In-diethylene triamine pentaacetic acid (DTPA), a small hydrophilic molecule, was cleared rapidly

49 ane [HT]-diethyneletriaminepentaacetic acid [DTPA]-gadolinium or indium 111-bis-5-HT-DTPA, respective

50 that diethylene triamine penta-acetic acid- (DTPA) extractable soil Zn concentration and grain Zn con

51 itional soil geochemical covariates affected DTPA-extractable soil Zn and Fe concentration and grain

52 168 h after injection of (111)In-[Lys40(Ahx-DTPA-(111)In)NH2]-exendin-4 ((111)In-DTPA-exendin-4) to

53 ically tested reference compound [Lys40-(AHX-DTPA-111In)NH2]exendin-4 and, thus, represent potential

54 ndin-4 was comparable to that of [Lys40-(AHX-DTPA-111In)NH2]exendin-4 at 1-48 h after injection.

55 -(AHX-DFO-89Zr)NH2]exendin-4 and [Lys40-(AHX-DTPA-111In)NH2]exendin-4 performed similarly well.

56 xperiments, clinically evaluated [Lys40-(AHX-DTPA-111In)NH2]exendin-4 was used as a reference compoun

57 ndustry "gold standards" DOTA (N(4)O(4)) and DTPA (N(3)O(5)).

58 A dextranated and DTPA-modified magnetofluorescent 20-nm nanoparticle was

59 La and HT29 cancer cells compared to DFO and DTPA.

60 improved stability when compared to DOTA and DTPA over 24 h.

61 id increased membrane damage, while EDTA and DTPA had transient effects.

62 enetriaminepentaacetic acid (DTPA) or benzyl-DTPA conjugated to a recombinant immunoglobulin G (IgG)

63 frames after injection of 7.4 MBq of (213)Bi-DTPA showed renal uptake and urinary clearance, visualiz

64 d with trastuzumab or human IgG followed by (DTPA)(n)-trastuzumab-(IRDye800)(m) and examined under a

65 nificant improvement to the acyclic chelator DTPA.

66 taacetate-tetra [DTPA]-A20FMDV2) or control (DTPA-A20FMDVran) peptide by nanoSPECT/CT imaging.

67 , the hybrid labeled somatostatin analog Cy5-DTPA-Tyr(3)-octreotate (DTPA is diethylene triamine pent

68 constant value was 387.7 +/- 97.9 nM for Cy5-DTPA-Tyr(3)-octreotate, whereas it was 120.5 +/- 18.1 nM

69 tate to 1.32% +/- 0.02% applied dose for Cy5-DTPA-Tyr(3)-octreotate.

70 or affinity and internalization rate for Cy5-DTPA-Tyr(3)-octreotate.

71 affinity and internalization capacity of Cy5-DTPA-Tyr(3)-octreotate were assessed in vitro.

72 x m734) (40 mg/m(2)), followed by (131)I-di-DTPA-indium bivalent hapten (1.8 GBq/m(2)) 4-6 d later.

73 o diethylenetriaminepentaacetic dianhydride (DTPA), allowing radiolabeling with the Auger electron-em

74 heir activation mechanism (bis-o-dianisidine-DTPA-Gd).

75 s measured either via exogenous markers (eg, DTPA, iohexol), or estimated using equations.

76 The Gd-EOB-DTPA in combination with regular T2-weighted MRCP may be

77 system and thus a decision to inject Gd-EOB-DTPA was taken.

78 he effect of gadoxetic acid disodium (Gd-EOB-DTPA) on T2 relaxation times and apparent diffusion coef

79 -diethylenetriamine-pentaacetic acid (Gd-EOB-DTPA) with dynamic contrast-enhanced MR imaging (DCEMRI)

80 drugs including gadoxetate disodium (Gd-EOB-DTPA).

81 of the hepatobiliary-specific GBCAs, Gd-EOB-DTPA, and gadobenate dimeglumine, primarily though OATP

82 The accuracy of Gd-EOB-DTPA-3T-MR significantly improves for lesions <20 mm.

83 ERIAL/73 patients underwent DCECT and Gd-EOB-DTPA-3T-MR.

84 ll HCA subtypes were hypoenhancing at Gd-EOB-DTPA-enhanced MR imaging in the hepatobiliary phase and

85 nt before and after administration of Gd-EOB-DTPA.

86 d after intravenous administration of Gd-EOB-DTPA.

87 A slower release rate of EPI(DTPA)(111)In than EPI(Tyr)(125)I was observed.

88 The results show that Eu-DTPA-monoamide complex 18b, which contains a quinoxanlin

89 ine (Fe-tCDTA Pearson R, 0.99; P = .0003; Fe-DTPA Pearson R, 0.97; P = .003).

90 ibed iron (Fe) chelates of pentetic acid (Fe-DTPA) and of trans-cyclohexane diamine tetraacetic acid

91 The volume transfer constant values for Fe-DTPA and Fe-tCDTA in the same tumors correlated well wit

92 R imaging with intravenous application of Fe-DTPA or Fe-tCDTA on day 1 and DCE MR imaging in the same

93 duced from 33.76% +/- 1.22% applied dose for DTPA-Tyr(3)-octreotate to 1.32% +/- 0.02% applied dose f

94 eotate, whereas it was 120.5 +/- 18.1 nM for DTPA-Tyr(3)-octreotate.

95 ly bound to an albumin (BSA)-Gd (gadolinium)-DTPA (diethylene triamine penta acetic acid)-biotin MRI

96 conventional liposome containing gadolinium-DTPA-BSA lipid.

97 A to simulate the distribution of gadolinium-DTPA (which represents its partition coefficient in well

98 ssue regions, as defined from the gadolinium-DTPA contrast-enhanced MR images, showed (18)F-NaF uptak

99 micelles and no enhancement using gadolinium-DTPA.

100 spin relaxation agents (5DSA, 16DSA, and Gd(DTPA-BMA)) indicated that the amphipathic alpha-helices

101 ontrast agent, gadopentetate dimeglumine (Gd(DTPA)(2-)), was used as the imageable cargo.

102 ramagnetic relaxation agent, gadodiamide (Gd(DTPA-BMA)).

103 ositive correlation between the amount of Gd(DTPA)(2-) released and T(1) was found.

104 The amount of Gd(DTPA)(2-) released was controlled by HIFU stimulation ti

105 g capabilities of MRgHIFU, the release of Gd(DTPA)(2-) stimulated by HIFU was pinpointed at the HIFU

106 fold more resistant to dissociation than [Gd(DTPA)(H2O)](2-).

107 Gd-DTPA-enhanced infarcts showed high (18)FDG uptake on day

108 n r(1) relaxivity over gadopentetic acid (Gd-DTPA) and have better X-ray absorption ability than rose

109 um diethylene-triamine penta-acetic acid (Gd-DTPA) as a contrast agent for dynamic contrast-enhanced

110 nium diethylenetrianime pentaacedic acid (Gd-DTPA) bisoleate (BOA) or gadolinium tetraazacyclododecan

111 nium diethylenetriamine pentaacetic acid (Gd-DTPA) enhanced MRI was performed at baseline, 3 hours an

112 MA) were compared with gadopentetic acid (Gd-DTPA) for infarct size determination, contrast-to-noise

113 inium diethylenetriaminepentaacetic acid (Gd-DTPA).

114 Immediately after Gd-DTPA administration, a high-signal-intensity rim was obs

115 noise ratio (infarct versus septum) after Gd-DTPA injection peaked at 10 minutes and returned to prei

116 5300/67 ms), T1 + Gd-DTPA (contrast agent Gd-DTPA at 0.2 mmol/kg).

117 g extravasation of the MRI contrast agent Gd-DTPA was significantly increased in both the sonicated t

118 ent (K(trans)) for an MRI contrast agent (Gd-DTPA) was estimated serially at 4-5 time points ranging

119 breast cancers underwent dynamic albumin-(Gd-DTPA)(30)-enhanced MR imaging followed by an initial dos

120 showed good agreement between Gd-ESMA and Gd-DTPA and were confirmed by ex vivo triphenyltetrazolium

121 d between delayed enhancement imaging and Gd-DTPA between days 7 and 21 (1.8+/- versus 3.8; P=ns), Gd

122 aminoglycan content for sodium iodide and Gd-DTPA only, diffusivity significantly increased for all c

123 +/- standard deviation) with Mn-PyC3A and Gd-DTPA was 476 +/- 77 and 538 +/- 120, respectively (P = .

124 es in diffusivities for sodium iodide and Gd-DTPA, with similar (but not significant) trends for sodi

125 ith various concentrations of Gd-DTPA and Gd-DTPA-BMA, and solutions of PEG 600 which served as a non

126 r diffusivity than sodium diatrizoate and Gd-DTPA.

127 apio anubis; n = 4) by using Mn-PyC3A and Gd-DTPA.

128 h various concentrations of Gd[DTPA-BMA], Gd-DTPA, or GdCl3.

129 egnant mice after administration of b-BSA-Gd-DTPA and analyzed using a new sub-voxel biophysical sign

130 recycling associated with the large b-BSA-Gd-DTPA conjugate.

131 porters with free biotin suppressed b-BSA-Gd-DTPA uptake.

132 ion of biotinylated contrast agent (b-BSA-Gd-DTPA).

133 dow for HCC chemotherapy, as monitored by Gd-DTPA-enhanced MRI as a noninvasive, clinically applicabl

134 ined for the three commonly used chelates Gd-DTPA, Gd-DTPA-BMA, and Gd-BT-DO3A, which were found to b

135 (Mn-PyC3A) to gadopentetate dimeglumine (Gd-DTPA) and to evaluate the excretion, pharmacokinetics, a

136 the three commonly used chelates Gd-DTPA, Gd-DTPA-BMA, and Gd-BT-DO3A, which were found to be 4.8 +/-

137 The degree of extracapsular Gd-DTPA enhancement was assessed in both conditions using s

138 The transfer coefficient Ktrans for Gd-DTPA and the drug concentrations showed a good linear co

139 nal small-molecule contrast agents, e.g., Gd-DTPA (diethylene triamine pentaacetic acid), used clinic

140 riaminepentaacetic acid gadolinium (III) (Gd-DTPA) and demonstrate their usefulness for MRI.

141 eased the signal intensity from tumors in Gd-DTPA-enhanced MRI.

142 n, and first-pass perfusion (0.03 mmol/kg Gd-DTPA bolus) at stress and rest (4-6 minutes IV adenosine

143 ulation kinetics than the small molecule, Gd-DTPA.

144 -DTPA enhancement and also in areas of no Gd-DTPA enhancement, which were confirmed histologically to

145 to create contrast was similar to that of Gd-DTPA alone.

146 incubated with various concentrations of Gd-DTPA and Gd-DTPA-BMA, and solutions of PEG 600 which ser

147 ns failed to produce detectable levels of Gd-DTPA in the back of the eye.

148 Assuming the velocity of Gd-DTPA to be equal to the fluid flow velocity, we used a s

149 Furthermore, MRI-based estimates of Gd-DTPA transport across these barriers might be useful to

150 Distribution and clearance of Gd-DTPA were measured using DCE-MRI.

151 environments show a loss of integrity of Gd-DTPA-BMA analogous to the one observed upon internalizat

152 s also been applied to assess the fate of Gd-DTPA-BMA-loaded liposomes upon their endosomal internali

153 by pulse radiolysis experiments (k((*)OH+Gd-DTPA) = 2.6 +/- 0.2 x 10(9) M(-1) s(-1), k((*)OH+Gd-DTPA

154 2.6 +/- 0.2 x 10(9) M(-1) s(-1), k((*)OH+Gd-DTPA-BMA) = 1.9 +/- 0.7 x 10(9) M(-1) s(-1), k((*)OH+Gd-

155 We injected 0.3 mmol/kg MPO-Gd (or Gd-DTPA as control) and performed magnetic resonance imagin

156 muscle at 9 seconds following Mn-PyC3A or Gd-DTPA injection.

157 Systematic injection of paramagnetic Gd-DTPA did not alter vitreous longitudinal relaxation time

158 gadolinium diethylenetriamine-pentaacid (Gd-DTPA).

159 significantly greater accumulation of PGC-Gd-DTPA-F in the graft area after immune attack initiated b

160 hours after intravenous injections of PGC-Gd-DTPA-F, followed by histologic examination.

161 PGC-Gd-DTPA-F-enhanced MR imaging allows for the in vivo assess

162 Comparing pre- and post-Gd-DTPA images demonstrated minimal choroidal contribution

163 inding was present in all regions showing Gd-DTPA enhancement and also in areas of no Gd-DTPA enhance

164 At 3.0 T, Gd-DTPA-BOA nanoparticles had an ionic r1 of 10.3 L . mmol(

165 455/9, 7 ms, T2 (TR/TE 5300/67 ms), T1 + Gd-DTPA (contrast agent Gd-DTPA at 0.2 mmol/kg).

166 nd 3.0% +/- 0.3 with alphavbeta3-targeted Gd-DTPA-BOA nanoparticles (P = .03).

167 se ratio peaked later and was higher than Gd-DTPA (40.8+/-10.4 versus 10.5+/-0.2; P<0.05).

168 and much longer blood retention time than Gd-DTPA in mice.

169 Together, these findings establish that Gd-DTPA-based DCE-MRI can noninvasively visualize tumor IFP

170 xcretion with similar pharmacokinetics to Gd-DTPA (area under the curve between 0 and 30 minutes, 20.

171 l infusion was successful in transporting Gd-DTPA to the posterior segment from an anterior infusion

172 data suggest that one may be able to use Gd-DTPA as a surrogate tracer to estimate DOX delivery to t

173 (Gd[DTPA-BMA]; Omniscan) as compared with Gd-DTPA and GdCl3 on the expression and production of cytok

174 MA in the postischemic scar compared with Gd-DTPA.

175 Loading of up to 30 wt % Gd-DTPA was achieved, and in vitro release occurred over 5

176 uilibrium (eqMRI) of the Gd(III) chelator Gd.DTPA, via the intraperitoneal route, was used to evaluat

177 etriaminepentaacetic acid bismethylamide (Gd[DTPA-BMA]; Omniscan) as compared with Gd-DTPA and GdCl3

178 incubated with various concentrations of Gd[DTPA-BMA], Gd-DTPA, or GdCl3.

179 cid [DTPA]-gadolinium or indium 111-bis-5-HT-DTPA, respectively).

180 n enzyme on its own in the presence of Eu(II)DTPA, displaying a strong activity in C2H2 reduction whi

181 catalytically active metal center in Eu(II)-DTPA-driven reactions.

182 m(II) diethylenetriaminepentaacetate [Eu(II)-DTPA].

183 c contrast enhanced imaging using HSA-Gd(III)DTPA.

184 21; and a difference in the mean increase in DTPA glomerular filtration rate in the hydroxycarbamide

185 -(111)In-DTPA-Tyr(3)-octreotate and (111)In -DTPA-Tyr(3)-octreotate (6.93 +/- 2.08 and 5.16 +/- 1.27,

186 and optical in vivo imaging of Cy5-(111)In -DTPA-Tyr(3)-octreotate were performed in NET-bearing mic

187 vement to the multiple isomers formed by [In(DTPA)](2-) and [In(DOTA)](-) under the same conditions.

188 abeled meal and 7.4 MBq (0.2 mCi) of (111)In-DTPA in 120 mL of water.

189 performed with 3.7 MBq (0.1 mCi) of (111)In-DTPA in 15 mL of water.

190 th ingestion of 3.7 MBq (0.1 mCi) of (111)In-DTPA in 300 mL of water.

191 gastrointestinal transit study using (111)In-DTPA with the standardized (99m)Tc-labeled solid meal.

192 al-beam radiotherapy, uptake on the [(111)In-DTPA(0)]octreotide scan, tumor load, grade 3-4 hematolog

193 ne metastases that were positive on [(111)In-DTPA(0)]octreotide somatostatin receptor scintigraphy (S

194 design a diagnostic imaging agent, ((111)In-DTPA)(n)-trastuzumab-(IRDye 800CW)(m), that is dual labe

195 ts were injected intravenously with ((111)In-DTPA)(n)-trastuzumab-(IRDye800)(m) and imaged with SPECT

196 muscle tissue slices indicated that ((111)In-DTPA)(n)-trastuzumab-(IRDye800)(m) bound only in tumor t

197 Dual-labeled ((111)In-DTPA)(n)-trastuzumab-(IRDye800)(m) may be an effective d

198 zumab 24 h before administration of ((111)In-DTPA)(n)-trastuzumab-(IRDye800)(m).

199 cting the mice with IRDye 800CW and ((111)In-DTPA)(p)-IgG-(IRDye800)(q), where "p" and "q" are the st

200 mice injected with IRDye 800CW and ((111)In-DTPA)(p)-IgG-(IRDye800)(q).

201 Results:(111)In-DTPA-anti-PD-L1 (dissociation constant, 0.6 +/- 0.1 nM)

202 Clearance of (111)In-DTPA-anti-PD-L1 from all organs occurred at 144 hours.

203 concentration on the distribution of (111)In-DTPA-anti-PD-L1 in a murine model of aggressive melanoma

204 The distribution of (111)In-DTPA-anti-PD-L1 in tumors as well as the spleen, liver,

205 , thus shifting the concentration of (111)In-DTPA-anti-PD-L1 into the blood stream and potentially in

206 These studies demonstrate that (111)In-DTPA-anti-PD-L1 is capable of identifying tumors that ov

207 ction with streptavidin complexed to (111)In-DTPA-biotin.

208 or biodistribution and NIRF imaging, (111)In-DTPA-D2B-IRDye800CW (2 mug, 0.55 MBq/mouse) was injected

209 micro-SPECT/CT and NIRF imaging with (111)In-DTPA-D2B-IRDye800CW (3 mug, 8.5 MBq/mouse) was performed

210 Dual-labeled (111)In-DTPA-D2B-IRDye800CW enables specific and sensitive detec

211 (111)In-DTPA-D2B-IRDye800CW specifically accumulated in subcutan

212 ndings warrant clinical studies with (111)In-DTPA-D2B-IRDye800CW to improve tumor detection and resec

213 referred to surgery on the basis of (111)In-DTPA-exendin-4 imaging alone.

214 All patients underwent (111)In-DTPA-exendin-4 imaging, 25 patients underwent surgery (w

215 (111)In-DTPA-exendin-4 SPECT/CT correctly detected 19 insulinoma

216 (111)In-DTPA-exendin-4 SPECT/CT could provide a good second-line

217 For 23 assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had a higher sensitivity (95% [9

218 s identified in separate patients by (111)In-DTPA-exendin-4 SPECT/CT.

219 s40(Ahx-DTPA-(111)In)NH2]-exendin-4 ((111)In-DTPA-exendin-4) to identify insulinomas.

220 d with (177)Lu-DOTA-Fab-PEG24-EGF or (111)In-DTPA-Fab-PEG24-EGF at the NOAEL, or with unlabeled immun

221 d tumor growth more effectively than (111)In-DTPA-Fab-PEG24-EGF because of a 9.3-fold-higher radiatio

222 ure to (177)Lu-DOTA-Fab-PEG24-EGF or (111)In-DTPA-Fab-PEG24-EGF or to monospecific (177)Lu- or (111)I

223 ted by (177)Lu-DOTA-Fab-PEG24-EGF or (111)In-DTPA-Fab-PEG24-EGF.

224 ab-PEG24-EGF was more cytotoxic than (111)In-DTPA-Fab-PEG24-EGF.

225 d 3 d after intravenous injection of (111)In-DTPA-labetuzumab-IRDye800CW (10 mug, 25 MBq).

226 jected dose/g) comparable to that of (111)In-DTPA-MN-14 but higher accumulation in the liver.

227 The biodistribution of (111)In-DTPA-MN-14-IRDye 800CW in mice with subcutaneous LS174T

228 g LS174T tumor nodules that received (111)In-DTPA-MN-14-IRDye 800CW, intraperitoneal tumor nodules co

229 e significantly better than those of (111)In-DTPA-OC (87% and 88%, respectively, P = 0.017).

230 OTATATE identified more lesions than (111)In-DTPA-OC and always at least as many.

231 t (64)Cu-DOTATATE is far superior to (111)In-DTPA-OC in diagnostic performance in NET patients.

232 th (64)Cu-DOTATATE and SPECT/CT with (111)In-DTPA-OC within 60 d.

233 epentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implementing (64)Cu-DOTATATE as

234 ected with (64)Cu-DOTATATE than with (111)In-DTPA-OC.

235 ot identified as disease-involved by (111)In-DTPA-OC.

236 (64)Cu-DOTATATE as a replacement for (111)In-DTPA-OC.

237 is and staging of NETs compared with (111)In-DTPA-octreotide and conventional imaging.

238 patients with negative or equivocal (111)In-DTPA-octreotide findings, (68)Ga-DOTATATE PET identifies

239 fied significantly more lesions than (111)In-DTPA-octreotide scintigraphy (P < 0.001).

240 ative or weakly positive findings on (111)In-DTPA-octreotide scintigraphy to determine whether (68)Ga

241 ative and 16 equivocal for uptake on (111)In-DTPA-octreotide scintigraphy underwent (68)Ga-DOTATATE P

242 d similar tumor uptake values of Cy5-(111)In-DTPA-Tyr(3)-octreotate and (111)In -DTPA-Tyr(3)-octreota

243 and compared with the performance of (111)In-DTPA-Tyr(3)-octreotate.

244 emonstrated that the tumor uptake of (111)In-DTPA-Tyr3-octreotate was not significantly different (P

245 Conversely for IR68144, DTPA-extractable Zn was positively correlated only with

246 nzyl-diethylenetriaminepentaacetic acid (ITC-DTPA) and subsequently radiolabeled with (111)In.

247 these cells with an affinity similar to its DTPA analogue.

248 In vivo CLI and SPECT imaging of (177)Lu-DTPA-11B6 uptake was performed on NMRI and BALB/c nude m

249 reas JVZ-007-cys was conjugated to maleimide-DTPA via the C-terminal cysteine.

250 As more DTPA is attached, the [M+H](+) peak of DTPA-IgG becomes

251 the DTPA attached per IgG increased as more DTPA was attached.

252 atostatin analog Cy5-DTPA-Tyr(3)-octreotate (DTPA is diethylene triamine pentaacetic acid) was synthe

253 For the high dose of CuO NPs, the amount of DTPA-extractable Cu in soil increased from 3 wt % immedi

254 rom the difference in the observed masses of DTPA-IgG and nonconjugated IgG divided by the molecular

255 The average number of moles of DTPA attached per mole of IgG was calculated from the di

256 crease in the heterogeneity in the number of DTPA attached to each molecule of IgG.

257 tration to accurately quantify the number of DTPA conjugated.

258 more DTPA is attached, the [M+H](+) peak of DTPA-IgG becomes broader and noisier.

259 "p" and "q" are the stoichiometric ratios of DTPA and IRDye 800CW bound per IgG antibody, respectivel

260 d to determine the molecular specificity of (DTPA)(n)-trastuzumab-(IRDye800)(m) in vitro in SKBr3 (HE

261 ity level and total soil Zn concentration on DTPA-extractable soil Zn concentration suggests potentia

262 5) between genotypes and Zn fertilization on DTPA (diethylenetriaminepentaacetic acid)-extractable so

263 Mice underwent MPO-Gd- or DTPA-Gd-enhanced MR imaging on days 6, 8, and 10 after i

264 evaluated nanosafety of Gd-lip containing PE-DTPA chelating Gd(+3) prepared by lipid film hydration m

265 of several diethylenetriamine pentaacetate (DTPA)-monoamide ligands bearing molecular "antennae" to

266 the frequently explored polyaminocarboxylate DTPA.

267 The resulting chelate-Rev (EDTA-Rev, DTPA-Rev, NTA-Rev, and DOTA-Rev) conjugates were used to

268 l)-diethylenetriaminepentaacetic acid (p-SCN-DTPA) via the lysines, whereas JVZ-007-cys was conjugate

269 tion of (18)F-FDG, bolus injection of (99)Tc-DTPA to simulate the distribution of gadolinium-DTPA (wh

270 pectively) in a degree comparable to (99m)Tc-DTPA (2.5 +/- 1.0, 1.5 +/- 0.2, and 0.8 +/- 0.3, respect

271 econd commercially available tracer, (99m)Tc-DTPA (diethylenetriaminepentaacetic acid), had minimal a

272 he promise of [(99m)Tc]TcO(4)(-) and (99m)Tc-DTPA as noninvasive imaging probes for a redox-sensitive

273 ction (glomerular filtration rate by (99m)Tc-DTPA clearance).

274 The mean reference GFR, based on (99m)Tc-DTPA clearance, was 74.9 mL/min/1.73 m(2) +/- 27.7 (stan

275 nd a significant correlation between (99m)Tc-DTPA content in brain and both the discrimination index

276 This procedure was repeated for the (99m)Tc-DTPA group after administration of 96 MBq (2.6 mCi) of t

277 ior of administered (99m)Tc-MAG3 and (99m)Tc-DTPA in experimental animals.

278 hanges were considerably greater for (99m)Tc-DTPA than for (99m)Tc-MAG3.

279 All patients underwent a (99m)Tc-DTPA urinary clearance examination on the same day to ob

280 min, respectively, whereas those for (99m)Tc-DTPA were 10.1 +/- 1 and 35 +/- 4 min, respectively.

281 min, respectively, whereas those of (99m)Tc-DTPA were 3.4 +/- 0.4 and 18.2 +/- 2 min, respectively.

282 diethylenetriamine pentaacetic acid ((99m)Tc-DTPA) is predominantly excreted by glomerular filtration

283 land White rabbits ((99m)Tc-MAG3 and (99m)Tc-DTPA) were used for the renography.

284 SPECT/CT imaging after injection of (99m)Tc-DTPA, an imaging marker of blood-brain barrier permeabil

285 the apparent distribution volume of (99m)Tc-DTPA.

286 beled diethylenetriaminepentaacetic acid (Tc-DTPA).

287 ioactivity after intravenous injection of Tc-DTPA represents an accurate, fast, and convenient way to

288 The rate of clearance of Tc-DTPA was measured as the slope (kappa) of the natural lo

289 ific (diethylenetriamine pentaacetate-tetra [DTPA]-A20FMDV2) or control (DTPA-A20FMDVran) peptide by

290 the first relapse (9.0 vs 2.7, P = .03) than DTPA-Gd, which also correlated well with the presence an

291 rescent enhancement observed thus far in the DTPA-type metal complexes.

292 ed mass and that of the stoichiometry of the DTPA attached per IgG increased as more DTPA was attache

293 d IgG divided by the molecular weight of the DTPA derivative.

294 ing was evaluated by conjugating A9 with the DTPA chelator and radiolabeling it with (111)In.

295 JVZ-007 was successfully conjugated to DTPA for radiolabeling with (111)In at room temperature.

296 bclinical inflammatory lesions compared with DTPA-Gd, including in cases in which there was no eviden

297 -brain barrier (BBB) breakdown detected with DTPA-Gd enhancement.

298 Treatment with DTPA further reduced ascorbate radical signals to below

299 SKBr3 cells were incubated with (DTPA)(n)-trastuzumab-(IRDye800)(m) or IRDye800CW or pret

300 h excess trastuzumab before incubation with (DTPA)(n)-trastuzumab-(IRDye800)(m) abolished this bindin

301 Soil Zn application increased Zn-DTPA concentration 3.7- to 5.6-times depending on the Zn